2024
DOI: 10.1111/resp.14656
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision

John A. Mackintosh,
Gregory Keir,
Lauren K. Troy
et al.

Abstract: Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung Foundation Australia (LFA) published a position statement on the treatment of IPF. Since that time, subsidized anti‐fibrotic therapy in the form of pirfenidone and nintedanib is now available in both Australia and New Zealand. More recently, evidence has been published in support of nintedanib for non‐IPF progressive pulmonary fi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 14 publications
(1 citation statement)
references
References 288 publications
(670 reference statements)
0
1
0
Order By: Relevance
“…2 In a recent publication in Respirology, an expert Australasian (TSANZ) group provides an overview of the best management of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) based primarily on evidence and guideline recommendations. 3 In most regards, this was an excellent document, a highly informative management blueprint that meets the needs of many patients. It should be stressed that this position statement is not a guideline, but adapts the guideline ethos to routine practice.…”
mentioning
confidence: 99%
“…2 In a recent publication in Respirology, an expert Australasian (TSANZ) group provides an overview of the best management of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) based primarily on evidence and guideline recommendations. 3 In most regards, this was an excellent document, a highly informative management blueprint that meets the needs of many patients. It should be stressed that this position statement is not a guideline, but adapts the guideline ethos to routine practice.…”
mentioning
confidence: 99%